, Influenza (Seasonal); c2018

W. Paul-glezen, J. K. Schmier, C. M. Kuehn, K. J. Ryan, and J. Oxford, The burden of influenza B: a structured literature review, American journal of public health, vol.103, issue.3, p.3673513, 2013.

I. Instituto-de-salud-carlos,

, Sistema de Vigilancia de la Gripe en España, pp.2017-2018

. Gobierno-de-aragón,

. Vigilancia-de-la-gripe, , pp.2001-2018

I. Instituto-de-salud-carlos,

L. Delgado-sanz, C. , J. , S. Flores, V. Simon et al.,

, Gac Sanit, vol.29, issue.4, pp.258-65, 2015.

J. Ryan, Y. Zoellner, B. Gradl, B. Palache, and J. Medema, Establishing the health and economic impact of influenza vaccination within the European Union 25 countries, Vaccine, vol.24, pp.6812-6834, 2006.

A. Perez-rubio, L. Platero, E. Bouza, and J. M. , Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes, Med Clin (Barc), vol.153, issue.1, pp.16-27, 2019.

S. Caini, P. Spreeuwenberg, G. F. Kusznierz, J. M. Rudi, R. Owen et al., Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, BMC Infect Dis, vol.18, issue.1, p.5994061, 1999.
URL : https://hal.archives-ouvertes.fr/pasteur-01925131

C. Hannoun, The evolving history of influenza viruses and influenza vaccines, Expert Rev Vaccines, vol.12, issue.9, pp.1085-94, 2013.

S. Caini, W. J. Alonso, C. E. Seblain, F. Schellevis, and J. Paget, The spatiotemporal characteristics of influenza A and B in the WHO European Region: can one define influenza transmission zones in Europe?, Euro Surveill, vol.22, issue.35, p.5587899, 2017.

C. Ambrose and M. Levin, The rationale for quadrivalent influenza vaccines, Human Vaccines & Immunotherapeutics, vol.8, issue.1, pp.81-89, 2012.

I. G. Barr and L. L. Jelley, The coming era of quadrivalent human influenza vaccines: who will benefit?, Drugs, vol.72, issue.17, pp.2177-85, 2012.

J. M. Eiros-bouza and A. Perez-rubio,

, Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia, vol.28, pp.39-46, 2015.

R. Ortiz-de-lejarazu, D. Domingo, J. , G. De-miguel, A. et al.,

, European Centre for Disease Prevention and Control [Internet]. Seasonal influenza vaccination in Europe-Vaccination recommendations and coverage rates for 2013-14 and 2014-15; c2016

S. Ministerio-de,

C. De-vacunació-n, Datos Estadísticos, 2018.

, WHO recommendations on the composition of influenza virus vaccines

, Risk assessment for seasonal influenza, 2017.

, Haut Conseil de la Santé Publique

, Grippe saisonnière: utilisation des vaccins quadrivalents inactivés; c2014

, Joint Committee on Vaccination and Immunisation

R. Koch-institut,

, Wissenschaftliche Begründung fü r die Empfehlung des quadrivalenten saisonalen Influenzaimpfstoffs; c2018, Epidemiologisches Bulletin

E. A. Belongia, B. A. Kieke, J. G. Donahue, R. T. Greenlee, A. Balish et al., Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. The Journal of infectious diseases, vol.199, pp.159-67, 2008.

M. Drummond, M. J. Sculpher, K. Claxton, G. L. Stoddart, and G. W. Torrance, Methods for the economic evaluation of health care programmes, 2015.

M. Uhart, H. Bricout, E. Clay, and N. Largeron, Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe, Hum Vaccin Immunother, vol.12, issue.9, pp.2259-68, 2016.

R. Pitman, D. Fisman, G. S. Zaric, M. Postma, M. Kretzschmar et al., Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol.15, pp.828-862, 2012.

A. K. Lugner, S. D. Mylius, and J. Wallinga, Dynamic versus static models in cost-effectiveness analyses of antiviral drug therapy to mitigate an influenza pandemic. Health economics, vol.19, pp.518-549, 2010.

W. J. Edmunds, G. F. Medley, and D. J. Nokes, Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective, Statistics in medicine, vol.18, issue.23, pp.3263-82, 1999.

B. M. Van-maanen, P. T. De-boer, F. C. Dolk, A. W. Friedrich, J. C. Wilschut et al., Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control. Expert Rev Vaccines, vol.16, 2017.

P. T. De-boer, B. M. Van-maanen, O. Damm, B. Ultsch, F. Dolk et al., A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert review of pharmacoeconomics & outcomes research, vol.17, pp.249-65, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01548937

P. Crepey, P. T. De-boer, M. J. Postma, and R. Pitman, Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respir Viruses, vol.9, p.4549101, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02460755

P. T. De-boer, P. Crepey, R. J. Pitman, B. Macabeo, A. Chit et al., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol.19, pp.964-75, 2016.

J. Mossong, N. Hens, M. Jit, P. Beutels, K. Auranen et al., Social contacts and mixing patterns relevant to the spread of infectious diseases, PLoS Med, vol.5, issue.3, p.2270306, 2008.

F. Carrat, E. Vergu, N. M. Ferguson, M. Lemaitre, S. Cauchemez et al., Time lines of infection and disease in human influenza: a review of volunteer challenge studies, American journal of epidemiology, vol.167, issue.7, pp.775-85, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02668741

, Principales series de población desde 1998, pp.1998-2018

N. M. Smith, J. S. Bresee, D. K. Shay, T. M. Uyeki, N. J. Cox et al., Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports, vol.55, pp.1-42, 2006.

N. A. Molinari, I. R. Ortega-sanchez, and M. L. Messonnier, The annual impact of seasonal influenza in the US: measuring disease burden and costs, Vaccine, vol.27, issue.25, pp.5086-96, 2007.

C. A. Diazgranados, M. Denis, and S. Plotkin, Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials, Vaccine, vol.31, issue.1, pp.49-57, 2012.

R. Gonzalez, M. Campins, J. A. Rodrigo, S. Uriona, and L. M. Vilca,

, Enferm Infecc Microbiol Clin, vol.33, issue.1, pp.22-28, 2015.

S. Ministerio-de,

S. Ministerio-de,

P. Estadístico, Conjunto Mínimo Bá sico de Datos-Hospitalización (CMBD-H), pp.1997-2015

A. Bengoa, M. San-martín, D. Vicente, and M. Larrañaga, Temporada gripal 2001-02 en una consulta de Pediatría en Atención Primaria. Bol S Vasco-Nav Pediatr, vol.36, pp.5-8, 2002.

C. R. Meier, P. N. Napalkov, Y. Wegmuller, T. Jefferson, and H. Jick, Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom, Eur J Clin Microbiol Infect Dis, vol.19, issue.11, pp.834-876, 2000.

, Oblikue consulting [Internet]. eSalud-Informació n económica del sector sanitario; c2007

, Consejo General de Colegios Oficiales de Farmacé uticos

M. Galante, O. Garin, E. Sicuri, F. Cots, A. Garcia-altes et al., Health services utilization, work absenteeism and costs of pandemic influenza A (H1N1) 2009 in Spain: a multicenter-longitudinal study, PLoS ONE, vol.7, issue.2, p.31696, 2012.

, Instituto Nacional de Estadística

I. Salarios, , pp.2009-2016

A. Garcia, R. Ortiz-de-lejarazu, R. J. Callejo, D. Cuervo, and J. , Morano Larragueta R. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain, Hum Vaccin Immunother, vol.12, issue.9, pp.2269-77, 2016.

M. Hollmann, O. Garin, M. Galante, M. Ferrer, A. Dominguez et al., Impact of influenza on healthrelated quality of life among confirmed (H1N1)2009 patients, PLoS One, vol.8, issue.3, p.60477, 2013.

, Instituto Nacional de Estadística

, Hipó tesis nacionales de evolució n demográ, 2018.

J. Lopez-bastida, J. Oliva, F. Antonanzas, A. Garcia-altes, R. Gisbert et al., Spanish recommendations on economic evaluation of health technologies. The European journal of health economics: HEPAC: health economics in prevention and care, vol.11, p.20405159, 2010.

S. Ministerio-de,

, BDCAP, pp.2011-2016

M. C. Weinstein, J. E. Siegel, M. R. Gold, M. S. Kamlet, and L. B. Russell, Recommendations of the Panel on Costeffectiveness in Health and Medicine, Jama, vol.276, issue.15, pp.1253-1261, 1996.

M. A. Koopmanschap and B. M. Van-ineveld, Towards a new approach for estimating indirect costs of disease, Social science & medicine, vol.34, issue.9, p.1631600, 1982.

M. A. Koopmanschap and F. F. Rutten, A practical guide for calculating indirect costs of disease, PharmacoEconomics, vol.10, issue.5, pp.460-466, 1996.

S. J. Davis, J. Faberman, and J. C. Haltiwanger, The establishment-level behaviour of vacancies and hiring, Q J Econ, vol.128, pp.581-622, 2013.

T. A. Kanters, C. Bouwmans, N. Van-der-linden, S. S. Tan, and L. Hakkaart-van-roijen, Update of the Dutch manual for costing studies in health care, PLoS One, vol.12, issue.11, p.5679627, 2017.

M. A. Koopmanschap, F. F. Rutten, B. M. Van-ineveld, and L. Van-roijen, The friction cost method for measuring indirect costs of disease, J Health Econ, vol.14, issue.2, pp.44-49, 1995.

J. Puig-junoy, J. Oliva-moreno, M. Trapero-bertran, J. Abellá-n-perpiñá-n, and M. Brosa-riestra, Guía y recomendaciones para la realizació n y presentació n de evaluaciones econó micas y aná lisis de impacto presupuestario de medicamentos en el á mbito del CatSalut, Barcelona: Servei Català de la Salut, 2014.

L. Vallejo-torres, B. García-lorenzo, I. Castilla, C. Valcá-rcel-nazco, L. García-pé-rez et al., Valor Monetario de un Año de Vida Ajustado por Calidad: Estimación empírica del coste de oportunidad en el Sistema Nacional de Salud

D. Thorrington, E. Van-leeuwen, M. Ramsay, R. Pebody, and M. Baguelin, Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England, BMC medicine, vol.15, issue.1, p.166, 2017.

M. Jit and R. Hutubessy, Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible? Applied health economics and health policy, vol.14, p.4871927, 2016.

R. Pradas-velasco, F. Antonanzas-villar, and M. P. Martinez-zarate, Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination, PharmacoEconomics, vol.26, issue.1, pp.45-56, 2008.

B. Ultsch, O. Damm, P. Beutels, J. Bilcke, B. Bruggenjurgen et al., Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community, PharmacoEconomics, vol.34, issue.3, p.4766233, 2016.

J. Mauskopf, B. Standaert, M. Connolly, A. Culyer, L. Garrison et al., Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes ResearchTask Force Report, Value in Health, vol.21, issue.10, pp.1133-1182, 2018.

A. T. Newall, N. Chaiyakunapruk, P. Lambach, and R. Hutubessy, WHO guide on the economic evaluation of influenza vaccination. Influenza Other Respir Viruses, vol.12, p.5820425, 2018.

, European Centre for Disease Prevention and Control

, Antimicrobial resistance surveillance in, Europe, 2016.